- Conditions
- Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
- Interventions
- Luspatercept
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,013 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 155
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 11,377
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumors, Non-small Cell Lung Cancer
- Interventions
- Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
- Drug
- Lead sponsor
- Xcovery Holdings, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 14
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 10 more
- Conditions
- Alternating Hemiplegia of Childhood
- Interventions
- Sodium Oxybate
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Thyroid Cancer
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Axillary Magseed
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Leukemia
- Interventions
- BAY2402234
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- New York, New York • The Bronx, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Advanced Solid Tumor
- Interventions
- Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- LUM/IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 34 more
- Conditions
- Vitrectomy
- Interventions
- Utravit High-Speed 10000 cpm Beveled Probe, standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm
- Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Healthy Participants, Alzheimer's Disease Dementia
- Interventions
- Emraclidine, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Cypress, California • San Diego, California • Hialeah, Florida + 8 more
- Conditions
- Multi-Drug Resistant Organism
- Interventions
- Allogeneic Microbiota in Glycerol (10%) (AMG)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Advanced/Metastatic Colorectal Adenocarcinoma
- Interventions
- BAY 3771249, Cetuximab
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Duarte, California • San Diego, California + 4 more
- Conditions
- Endometriosis, Diagnosis
- Interventions
- MetriDx
- Diagnostic Test
- Lead sponsor
- Hera Biotech, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Saginaw, Michigan • Corpus Christi, Texas • Houston, Texas
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- risdiplam, omeprazole
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more
- Conditions
- Connective Tissue Disorders, Osteogenesis Imperfecta, Bone Diseases, Metabolic, Melorheostosis
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Up to 70 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- decitabine, valproic acid, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Nasal Obstruction
- Interventions
- Vivaer Stylus
- Device
- Lead sponsor
- Aerin Medical
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 8
- States / cities
- Fresno, California • Colorado Springs, Colorado • Oradell, New Jersey + 5 more
- Conditions
- T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma, Adult T Cell Leukemia, Adult T Cell Lymphoma, T Cell Prolymphocytic Leukemia, Extranodal NK/T-cell Lymphoma, Transformed Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Interventions
- WU-CART-007
- Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Cancer
- Interventions
- Cohort 1 neo-adjuvant, Cohort 2 neo-adjuvant, Cohort 1 adjuvant, Cohort 2 adjuvant
- Drug
- Lead sponsor
- William Sikov MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 5
- States / cities
- Duarte, California • New Haven, Connecticut • Providence, Rhode Island
- Conditions
- Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer
- Interventions
- LN-145, Cyclophosphamide, Fludarabine, Interleukin-2
- Biological · Drug
- Lead sponsor
- Karam Khaddour, MD, MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, Multigated Acquisition Scan
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 192
- States / cities
- Birmingham, Alabama • Kingman, Arizona • Arroyo Grande, California + 155 more
- Conditions
- Cancer
- Interventions
- GSK2118436 75 mg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more
- Conditions
- Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
- Interventions
- Whole body scan
- Procedure
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2033
- U.S. locations
- 8
- States / cities
- San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Hypertriglyceridemia
- Interventions
- rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey